EMA (EU)
GUIDANCE FINAL
Concept paper on the guideline revision on good pharmacogenomic practice
Published: 10/6/2026Detected: 10/6/2026
Summary preview
Revises EMA’s good pharmacogenomic practice framework to reflect advancing genomics technologies and to improve regulatory usability across medicines development and clinical use.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system12/7/2026
- Unified application programming interface (API) platform event12/2/2026
- Committee for Advanced Therapies (CAT): 2-4 December 202612/2/2026
- Committee for Medicinal Products for Veterinary Use (CVMP): 1-3 December 202612/1/2026
- Committee for Orphan Medicinal Products (COMP): 1-3 December 202612/1/2026